Back to search
FDAFDA · Food and drugs·Recall number D-1040-2017

Testosterone Cypionate + Progesterone, 200 mg/ 2.5 mg/mL ,10 mL amber glass vials, Rx Only, Compounded by AXIA Pharmaceutical, Los Angeles, CA 90025

Published August 9, 2017 · Recall initiated: July 12, 2017

Summary

FDA records drug Class II recall D-1040-2017, published August 9, 2017 and initiated July 12, 2017. Recalling firm: Fusion IV Pharmaceuticals, Inc. dba Axia Pharmaceutical; Status: Terminated; Reported quantity: 120 vials; Lot: Lot # 03022017+44906; BUD 08/29/17. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Fusion IV Pharmaceuticals, Inc. dba Axia Pharmaceutical
Distributor
There were only one customer in California
Lot
Lot # 03022017+44906; BUD 08/29/17
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Testosterone Cypionate + Progesterone, 200 mg/ 2.5 mg/mL ,10 mL amber glass vials, Rx Only, Compounded by AXIA Pharmaceutical, Los Angeles, CA 90025 recalled?

Yes. FDA published recall D-1040-2017 on August 9, 2017. Reported hazard: CGMP Deviations

What should I do if I have this product?

Voluntary: Firm initiated · Letter